Availability of 5-fluorouracil and High-concentration Cisplatin with Short-term Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma | Chapter 9 | Current Innovations in Medicine and Medical Science vol. 1

 The purpose of this study was to evaluate the effectiveness and utility of 5-fluorouracil (5-FU) and high-concentration cisplatin in advanced hepatocellular carcinoma (HCC) patients receiving short-term (3-day FPL) hepatic arterial infusion chemotherapy.

30 patients with advanced HCC that was unresectable were included in the study. A fine-powder formulation of cisplatin in suspended, pre-warmed lipiodol on Day 2 and hepatic arterial infusion chemotherapy with 5-FU on Days 1-3 were administered to the patients via the implanted port system every 4 to 10 weeks. CT was utilised to evaluate the tumour response one month later. The prognosis is often bad for patients with advanced HCC. The study's findings showed that every patient had signs of portal vein invasion (Vp2-4). Seven patients had stable disease, eight patients had partial responses, and four patients had complete responses (SD). Overall survival (OS) and progression-free survival (PFS) had medians of 198 days and 452 days, respectively. The successful disease control group (CR, PR, and SD) had an OS that was considerably longer than the disease progression group (P .005). Three-day FPL demonstrated efficacy and tolerance in patients with advanced HCC due to its rapid delivery than conventional FP therapy. Thus, recurring 3-day FPL, which looks to be efficient, appears to enhance the prognosis and quality of life of patients with advanced HCC.

Author(s) Details:

Yutaka Yata,
Department of Hepatology, Osaka Metropolitan University, Japan and  Department of Gastroenterology, Hanwa Memorial Hospital, Japan.

Please see the link here: https://stm.bookpi.org/CIMMS-V1/article/view/8108

Determination of Cisplatin Effect on Head and Neck Squamous Cell Carcinoma Modulated by Erk1/2 Protein Kinases | Chapter 14 | Current Practice in Medical Science Vol. 8

The aim of this study was to investigate the role of extracellular signal-regulated kinases (ERK1/2) and/or p53 activation in the apoptotic process induced by cisplatin-CisPT treatment on two head and neck squamous cell carcinoma cell lines (FaDu and PE/CA-PJ49) and how curcumin (CRM) used as an adjuvant supports it. According to data, CRM enhances CisPt activity. In both cell lines, CRM raised the phosphorylation of the p53 protein. CisPt altered the phosphorylation of the p53 protein in PE/CA-PJ49 cells but enhanced it in FaDu cells. The constitutive expression of activated ERK1/2 protein-kinase varied in the two tumour cell lines under investigation. The activation status of ERK1/2 was a factor in the cell processes that CisPt and/or CRM induced, including cell proliferation and death. Our results suggest that the phosphorylation of p53 during the apoptotic response to CRM treatment may need ERK1/2. In both tumour cell lines, combination treatments (CisPt and CRM) resulted in apoptosis that was dependent on p53 phosphorylation and ERK1/2 activation. Finally, ERK1/2 may affect cell proliferation and/or death depending on the type of therapeutic drug, the properties of the cells, and the level of ERK1/2 activation.

 

Author (s) Details

Marinela Bostan

Stefan S. Nicolau Institute of Virology, Center of Immunology, Bucharest, Romania and  Victor Babes National Institute of Pathology, Bucharest, Romania.

Georgiana Gabriela Petrica-Matei

Department of Cytogenetics, Personal Genetics - Medical Genetics Center, Bucharest, Romania.

Gabriela Ion

Stefan S. Nicolau Institute of Virology, Center of Immunology, Bucharest, Romania.

Nicoleta Radu

University of Agronomic Sciences and Veterinary Medicine of Bucharest, Biotechnology Dept.& National Institute for Chemistry and Petrochemistry R&D of Bucharest, Romania.

Mirela Mihaila

Stefan S. Nicolau Institute of Virology, Center of Immunology, Bucharest, Romania.

Razvan Hainarosie

Prof. Dr. Dorin Hociota Institute of Phonoaudiology and Functional ENT Surgery, Bucharest, Romania.

Lorelei Irina Brasoveanu

Stefan S. Nicolau Institute of Virology, Center of Immunology, Bucharest, Romania.

Viviana Roman

Stefan S. Nicolau Institute of Virology, Center of Immunology, Bucharest, Romania.

Carolina Constantin

Victor Babes National Institute of Pathology, Bucharest, Romania.

Monica Teodora Neagu

Victor Babes National Institute of Pathology, Bucharest, Romania.

 

Please see the link here:-  https://stm.bookpi.org/CPMS-V8/article/view/7803

Study on Chemotherapy Agents in Saliva through Spectrometry and Chromatography Methods Correlated with Periodontal Status in Oncology Patients | Chapter 8 | Innovations in Science and Technology Vol. 1

 This paper describes the usage of a battery-based dynamic voltage restorer (DVR) to alleviate voltage sag and swell. During sag/swell, the DVR is a three-phase controlled voltage source with a magnitude and angle that adds/subtracts from the source voltage. In each phase, the DVR can inject a voltage of the required magnitude and phase at the fundamental frequency. The DVR can restore the load voltage in milliseconds. DVR can fix voltage sag and voltage swell problems fast and effectively. To estimate reference voltages, the Synchronous Reference Frame Theory (SRFT) is employed, and gate pulses are generated by monitoring the source, load terminal voltages, and supply currents. The reduction of voltage sag and swell using SRFT for battery-based DVR is simulated using MATLAB/ SIMULINK and the power system Block set (PSB) toolboxes.

Author(S) Details

Diana Cristala Kappenberg Nitescu
Periodontology Department, Faculty of Dentistry, “Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania.

Liliana Pasarin
Periodontology Department, Faculty of Dentistry, “Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania.

Silvia Martu
Periodontology Department, Faculty of Dentistry, “Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania.

Cornelia Teodorescu
Periodontology Department, Faculty of Dentistry, “Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania.

Bogdan Vasiliu
Periodontology Department, Faculty of Dentistry, “Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania.

Ioana Mârtu
Dental Technology Department, Faculty of Dentistry, “Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania.

Ionut Luchian
Periodontology Department, Faculty of Dentistry, “Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania.

Sorina Mihaela Solomon
Periodontology Department, Faculty of Dentistry, “Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania.

View Book:- https://stm.bookpi.org/IST-V1/article/view/5082